C77.9: Secondary and unspecified malignant neoplasm of lymph node, unspecified

C77.9, secondary and unspecified malignant neoplasm of lymph node, unspecified, is listed as a covered diagnosis in 6 Medicare billing and coding articles that apply to 48 HCPCS Level II codes, including Q2043 (Sipuleucel-t, minimum of 50 million autologous cd54+ cells…), J9217 (Leuprolide acetate (for depot suspension), 7.5 mg), J1952 (Leuprolide injectable, camcevi, 1 mg). 4 of these codes have a 2026 DMEPOS fee schedule amount; E0783 pays $9,917.33 to $11,667.45 (NU) depending on the state. The articles come from 4 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.

HCPCS Level II codes with C77.9 as a covered diagnosis

CodeDescriptionMedicare coverageDMEPOS fee 2026 (state range)Articles listing it
Q2043Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusionSpecial coverage instructions apply—1
J9217Leuprolide acetate (for depot suspension), 7.5 mgSpecial coverage instructions apply—1
J1952Leuprolide injectable, camcevi, 1 mgCarrier judgment—1
J3315Injection, triptorelin pamoate, 3.75 mgSpecial coverage instructions apply—1
J1954Injection, leuprolide acetate for depot suspension (lutrate depot), 7.5 mgCarrier judgment—1
J9202Goserelin acetate implant, per 3.6 mgSpecial coverage instructions apply—1
J1950Injection, leuprolide acetate (for depot suspension), per 3.75 mgSpecial coverage instructions apply—1
J3316Injection, triptorelin, extended-release, 3.75 mgSpecial coverage instructions apply—1
J9218Leuprolide acetate, per 1 mgSpecial coverage instructions apply—1
J9219Leuprolide acetate implant, 65 mgSpecial coverage instructions apply—1
J9225Histrelin implant (vantas), 50 mgSpecial coverage instructions apply—1
J0461Injection, atropine sulfate, 0.01 mgSpecial coverage instructions apply—1
J0153Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds)Special coverage instructions apply—1
J1250Injection, dobutamine hydrochloride, per 250 mgSpecial coverage instructions apply—1
J0280Injection, aminophyllin, up to 250 mgSpecial coverage instructions apply—1
J1245Injection, dipyridamole, per 10 mgSpecial coverage instructions apply—1
J0881Injection, darbepoetin alfa, 1 microgram (non-esrd use)Special coverage instructions apply—1
J0885Injection, epoetin alfa, (for non-esrd use), 1000 unitsSpecial coverage instructions apply—1
Q5106Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 unitsSpecial coverage instructions apply—1
J0882Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis)Special coverage instructions apply—1
Q5105Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 unitsSpecial coverage instructions apply—1
J0890Injection, peginesatide, 0.1 mg (for esrd on dialysis)Carrier judgment—1
Q4081Injection, epoetin alfa, 100 units (for esrd on dialysis)Special coverage instructions apply—1
Q5110Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgramSpecial coverage instructions apply—1
Q5125Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgramCarrier judgment—1

23 more codes are listed. See every code with payment by region in Caduvo.

Medicare policy articles listing C77.9

A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.

Other C77 diagnoses (Secondary and unspecified malignant neoplasm of lymph nodes)

Frequently asked questions

Does Medicare cover C77.9 (Secondary and unspecified malignant neoplasm of lymph…)?

Medicare covers items and services, not diagnoses. 6 Medicare billing and coding articles list C77.9 as a covered diagnosis for 48 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.

Which HCPCS codes can be billed with ICD-10 C77.9?

The Level II codes from the policies most specific to this diagnosis are Q2043 (Sipuleucel-t, minimum of 50 million autologous cd54+ cells…, 1 article); J9217 (Leuprolide acetate (for depot suspension), 7.5 mg, 1 article); J1952 (Leuprolide injectable, camcevi, 1 mg, 1 article); J3315 (Injection, triptorelin pamoate, 3.75 mg, 1 article); J1954 (Injection, leuprolide acetate for depot suspension…, 1 article). Code choice depends on the item supplied; check each code's descriptor.

What does Medicare pay for equipment billed with C77.9?

Under the 2026 DMEPOS fee schedule (non-rural state fees): E0783 $9,917.33 to $11,667.45 (NU); E0786 $10,969.75 to $11,380.88 (NU); E0782 $5,200.92 to $6,118.73 (NU); E0785 $572.38 to $673.39 (KF). Medicare pays 80% of the allowed amount after the Part B deductible.

Which Medicare policy articles list C77.9?

A55719 (Sipuleucel-T (Provenge®) - Coverage Criteria for Prostate Cancer – Clarification); A52453 (Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs); A54768 (Billing and Coding: Cardiac Blood Pool Imaging (Multiple Gated Acquisition Scanning- MUGA, Ventriculography) When Performed in Conjunction with Cardiotoxic Chemotherapy), and 3 more articles.

What is ICD-10-CM code C77.9?

C77.9 is the ICD-10-CM code for secondary and unspecified malignant neoplasm of lymph node, unspecified, in category C77 (Secondary and unspecified malignant neoplasm of lymph nodes), chapter 2: Neoplasms.

Next steps

Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.

Chapter 2: Neoplasms · All diagnoses · HCPCS lookup